

# Giovanni Barosi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6394841/publications.pdf>

Version: 2024-02-01

171  
papers

16,421  
citations

23567

58  
h-index

15732

125  
g-index

173  
all docs

173  
docs citations

173  
times ranked

8835  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transplant indications, guidelines and recommendations: Caveat Emptor. Bone Marrow Transplantation, 2022, 57, 149-151.	2.4	2
2	Everyone is entitled to his or her own opinion but not to their own facts*. British Journal of Haematology, 2022, 196, 1290-1292.	2.5	0
3	Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel. Critical Reviews in Oncology/Hematology, 2022, 172, 103623.	4.4	7
4	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology, 2022, 9, e301-e311.	4.6	46
5	Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story. Blood Advances, 2022, 6, 2331-2333.	5.2	13
6	Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia, 2021, 35, 468-475.	7.2	7
7	Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. Leukemia, 2021, 35, 1197-1202.	7.2	9
8	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	5.2	8
9	COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021034.	1.3	4
10	Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis. Cancers, 2021, 13, 2552.	3.7	9
11	Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes. Genes, 2021, 12, 1271.	2.4	4
12	New Markers of Disease Progression in Myelofibrosis. Cancers, 2021, 13, 5324.	3.7	6
13	Primary myelofibrosis: rs2010963 VEGFA polymorphism favors a profibrotic phenotype and is associated with higher risk of thrombosis. Leukemia Research, 2021, 111, 106730.	0.8	3
14	VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis. TH Open, 2021, 05, e513-e520.	1.4	1
15	Plasma sIL-2R $\alpha$ levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation. Leukemia Research, 2020, 90, 106319.	0.8	7
16	Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. Blood, 2020, 135, 133-144.	1.4	52
17	Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. Blood Cancer Journal, 2019, 9, 61.	6.2	25
18	Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity. PLoS ONE, 2019, 14, e0220189.	2.5	3

#	ARTICLE	IF	CITATIONS
19	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019, 34, 84-94.	5.7	35
20	Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?. <i>Leukemia</i> , 2019, 33, 588-596.	7.2	8
21	Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. <i>Blood</i> , 2019, 133, 2802-2808.	1.4	12
22	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. <i>Leukemia Research</i> , 2019, 81, 88-94.	0.8	11
23	Response to the Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?". <i>Leukemia</i> , 2019, 33, 1301-1302.	7.2	0
24	Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. <i>Blood Advances</i> , 2019, 3, 1729-1737.	5.2	105
25	Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 855-860.	2.0	13
26	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018, 32, 1057-1069.	7.2	415
27	Is there expert consensus on expert consensus?. <i>Bone Marrow Transplantation</i> , 2018, 53, 1055-1060.	2.4	15
28	The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. <i>American Journal of Hematology</i> , 2018, 93, 615-622.	4.1	8
29	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018, 36, 310-318.	1.6	373
30	Role of TGF- $\beta$ 1/miR-382a-5p/ SOD 2 axis in the induction of oxidative stress in CD 34+ cells from primary myelofibrosis. <i>Molecular Oncology</i> , 2018, 12, 2102-2123.	4.6	19
31	Response to "Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions" by Heidel et al.. <i>Leukemia</i> , 2018, 32, 2727-2728.	7.2	2
32	Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. <i>Leukemia</i> , 2018, 32, 2077-2081.	7.2	30
33	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders: A consensus project of the Italian Society of Hematology. <i>Leukemia Research</i> , 2017, 58, 63-72.	0.8	25
34	Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. <i>Leukemia Research</i> , 2017, 60, 18-23.	0.8	27
35	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. <i>Blood</i> , 2017, 129, 3227-3236.	1.4	137
36	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. <i>Blood</i> , 2017, 130, 1768-1771.	1.4	52

#	ARTICLE	IF	CITATIONS
37	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. <i>American Journal of Hematology</i> , 2017, 92, 1062-1067.	4.1	33
38	Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. <i>American Journal of Pathology</i> , 2017, 187, 1879-1892.	3.8	17
39	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2017, 92, 187-195.	4.1	41
40	CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. <i>Oncotarget</i> , 2017, 8, 54082-54095.	1.8	25
41	miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. <i>Oncotarget</i> , 2017, 8, 21380-21397.	1.8	13
42	Thrombopoietin/TGF- $\beta$ 1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis. <i>Stem Cells</i> , 2016, 34, 1123-1133.	3.2	49
43	Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. <i>European Journal of Haematology</i> , 2016, 97, 554-561.	2.2	9
44	Reduced frequency of circulating CD4 <sup>+</sup> CD25 <sup>bright</sup> CD127 <sup>low</sup> FOXP3 <sup>+</sup> regulatory T cells in primary myelofibrosis. <i>Blood</i> , 2016, 128, 1660-1662.	1.4	13
45	Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis. <i>American Journal of Hematology</i> , 2016, 91, 709-713.	4.1	6
46	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 151-159.	1.6	56
47	Altered fibronectin expression and deposition by myeloproliferative neoplasm-derived mesenchymal stromal cells. <i>British Journal of Haematology</i> , 2016, 172, 140-144.	2.5	18
48	Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 324-329.	2.0	56
49	Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis. <i>PLoS ONE</i> , 2016, 11, e0156990.	2.5	3
50	Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal. <i>Clinical Investigation</i> , 2015, 5, 643-651.	0.0	0
51	Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis. <i>OncoTargets and Therapy</i> , 2015, 8, 1091.	2.0	17
52	Dysregulation of VEGF-induced proangiogenic Ca <sup>2+</sup> oscillations in primary myelofibrosis-derived endothelial colony-forming cells. <i>Experimental Hematology</i> , 2015, 43, 1019-1030.e3.	0.4	46
53	Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 507-513.	0.4	13
54	Activation of non-canonical TGF- $\beta$ 1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 234-241.	1.4	31

#	ARTICLE	IF	CITATIONS
55	Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 362-369.	2.3	1
56	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. <i>Nature Communications</i> , 2015, 6, 6691.	12.8	145
57	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 75-85.	0.4	32
58	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. <i>Blood</i> , 2014, 124, 1062-1069.	1.4	340
59	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. <i>Cancer</i> , 2014, 120, 513-520.	4.1	165
60	Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 129-140.	1.7	43
61	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. <i>Leukemia Research</i> , 2014, 38, 1269-1277.	0.8	13
62	An Immune Dysregulation in MPN. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 331-339.	2.3	75
63	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. <i>Leukemia Research</i> , 2014, 38, 155-160.	0.8	28
64	CD14 <sup>bright</sup> CD16 <sup>low</sup> intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis. <i>Experimental Hematology</i> , 2014, 42, 244-246.	0.4	9
65	miRNA-mRNA integrative analysis in primary myelofibrosis CD34 <sup>+</sup> cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. <i>Blood</i> , 2014, 124, e21-e32.	1.4	105
66	A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group. <i>Blood</i> , 2014, 124, 3192-3192.	1.4	1
67	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. <i>Blood</i> , 2014, 124, 405-405.	1.4	47
68	Enhanced Expression of Stim, Orai, and TRPC Transcripts and Proteins in Endothelial Progenitor Cells Isolated from Patients with Primary Myelofibrosis. <i>PLoS ONE</i> , 2014, 9, e91099.	2.5	60
69	A phase II study of ruxolitinib in combination with hydroxycarbamide in patients with polycythemia vera unresponsive to hydroxycarbamide monotherapy. <i>British Journal of Haematology</i> , 2013, 161, 688-694.	2.5	109
70	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013, 122, 1395-1398.	1.4	286
71	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. <i>Blood</i> , 2013, 122, 4047-4053.	1.4	383
72	SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 185-192.	4.1	32

#	ARTICLE	IF	CITATIONS
73	No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis. <i>Haematologica</i> , 2013, 98, e83-e84.	3.5	4
74	Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. <i>Blood</i> , 2013, 121, 360-368.	1.4	102
75	Characterization of the TGF- $\beta$ 1 signaling abnormalities in the Gata1 <sup>low</sup> mouse model of myelofibrosis. <i>Blood</i> , 2013, 121, 3345-3363.	1.4	86
76	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. <i>Blood</i> , 2013, 121, 4778-4781.	1.4	219
77	Involvement of TGF $\beta$ 1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis. <i>Haematologica</i> , 2013, 98, 514-517.	3.5	29
78	The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT). <i>Blood</i> , 2013, 122, 4070-4070.	1.4	15
79	JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis. <i>PLoS ONE</i> , 2013, 8, e59791.	2.5	15
80	Emerging targeted therapies in myelofibrosis. <i>Expert Review of Hematology</i> , 2012, 5, 313-324.	2.2	4
81	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. <i>Journal of Clinical Oncology</i> , 2012, 30, 4098-4103.	1.6	344
82	JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. <i>New England Journal of Medicine</i> , 2012, 366, 787-798.	27.0	1,543
83	A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. <i>Blood</i> , 2012, 120, 3112-3117.	1.4	33
84	Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis. <i>PLoS ONE</i> , 2012, 7, e35631.	2.5	85
85	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 875-888.	1.8	28
86	JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2012, 36, e7-e9.	0.8	17
87	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 459-466.	0.8	7
88	Management of Myeloproliferative Neoplasms: From Academic Guidelines to Clinical Practice. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 50-56.	2.3	19
89	Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera. <i>Blood</i> , 2012, 120, 804-804.	1.4	6
90	Current Clinical Needs. , 2012, , 149-161.		0

#	ARTICLE	IF	CITATIONS
91	Evaluation of the bioactive and total transforming growth factor $\hat{2}1$ levels in primary myelofibrosis. <i>Cytokine</i> , 2011, 53, 100-106.	3.2	29
92	In Vitro Megakaryocyte Differentiation and Proplatelet Formation in Ph-Negative Classical Myeloproliferative Neoplasms: Distinct Patterns in the Different Clinical Phenotypes. <i>PLoS ONE</i> , 2011, 6, e21015.	2.5	48
93	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. <i>Blood</i> , 2011, 118, 401-408.	1.4	280
94	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. <i>Blood</i> , 2011, 118, 2069-2076.	1.4	144
95	EZH2 mutational status predicts poor survival in myelofibrosis. <i>Blood</i> , 2011, 118, 5227-5234.	1.4	242
96	The European LeukemiaNet: achievements and perspectives. <i>Haematologica</i> , 2011, 96, 156-162.	3.5	15
97	Splenectomy produces a rapid but transient decrease of the frequency of circulating CD34 <sup>+</sup> haematopoietic progenitor cells in primary myelofibrosis. <i>British Journal of Haematology</i> , 2011, 152, 665-667.	2.5	3
98	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011, 29, 761-770.	1.6	724
99	Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: Deconstructing a myth?. <i>Leukemia Research</i> , 2011, 35, 563-565.	0.8	4
100	Therapeutic approaches in myelofibrosis. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1597-1611.	1.8	25
101	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. <i>Haematologica</i> , 2011, 96, 315-318.	3.5	160
102	Conventional and Investigational Therapy for Primary Myelofibrosis. , 2011, , 117-138.		1
103	Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. <i>Blood</i> , 2010, 116, 1051-1055.	1.4	56
104	Consensus conference on the use of $^{90}\text{Y}$ -triumab $\hat{c}$ britumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology. <i>American Journal of Hematology</i> , 2010, 85, 147-155.	4.1	5
105	Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. <i>American Journal of Hematology</i> , 2010, 85, 616-619.	4.1	18
106	Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?. <i>Leukemia Research</i> , 2010, 34, 1119-1120.	0.8	16
107	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. <i>British Journal of Haematology</i> , 2010, 148, 961-963.	2.5	144
108	A pilot study of the Histone $\hat{c}$ Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2010, 150, 446-455.	2.5	202

#	ARTICLE	IF	CITATIONS
109	High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis. PLoS ONE, 2010, 5, e15277.	2.5	30
110	Thrombosis in primary myelofibrosis: incidence and risk factors. Blood, 2010, 115, 778-782.	1.4	216
111	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 2009, 113, 4829-4833.	1.4	229
112	Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. Journal of Clinical Oncology, 2009, 27, 4563-4569.	1.6	213
113	Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2009, 94, 102-112.	3.5	23
114	JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica, 2009, 94, 144-146.	3.5	35
115	Novel strategies for patients with chronic myeloproliferative disorders. Current Opinion in Hematology, 2009, 16, 129-134.	2.5	11
116	Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica, 2009, 94, 550-565.	3.5	66
117	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 2009, 113, 2895-2901.	1.4	1,110
118	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 2009, 114, 1477-1483.	1.4	196
119	Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. Blood, 2009, 114, 3127-3130.	1.4	79
120	Hypermethylation of CXCR4 Promoter in CD34+ Cells from Patients with Primary Myelofibrosis. Stem Cells, 2008, 26, 1920-1930.	3.2	91
121	A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2008, 10, 435-441.	2.8	47
122	From Palliation to Epigenetic Therapy in Myelofibrosis. Hematology American Society of Hematology Education Program, 2008, 2008, 83-91.	2.5	13
123	MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. Blood, 2008, 111, 4418-4418.	1.4	30
124	Characteristics and clinical correlates of MPL 515W&gt;L/K mutation in essential thrombocythemia. Blood, 2008, 112, 844-847.	1.4	216
125	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 2007, 110, 1092-1097.	1.4	808
126	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood, 2007, 110, 4030-4036.	1.4	233



#	ARTICLE	IF	CITATIONS
127	New and Old Treatment Modalities in Primary Myelofibrosis. <i>Cancer Journal (Sudbury, Mass )</i> , 2007, 13, 377-383.	2.0	53
128	The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. <i>Blood Cells, Molecules, and Diseases</i> , 2007, 38, 280-286.	1.4	60
129	Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. <i>Blood</i> , 2007, 110, 986-993.	1.4	186
130	Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. <i>Haematologica</i> , 2007, 92, 95-100.	3.5	341
131	Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). <i>Leukemia Research</i> , 2007, 31, 737-740.	0.8	288
132	Anaemia characterises patients with myelofibrosis harbouring MplW515L/Kmutation. <i>British Journal of Haematology</i> , 2007, 137, 244-247.	2.5	153
133	New consensus: a unified definition of clinical resistance and/or intolerance to hydroxyurea in essential thrombocythaemia. <i>European Journal of Haematology</i> , 2007, 79, 24-26.	2.2	2
134	Molecular Profiling of CD34+Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1). <i>Stem Cells</i> , 2007, 25, 165-173.	3.2	111
135	Management of Myelofibrosis. , 2007, , 125-142.		1
136	Myelofibrosis with myeloid metaplasia: Disease overview and non-transplant treatment options. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 495-517.	1.7	31
137	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , 2006, 108, 1497-1503.	1.4	317
138	Allogeneic hematopoietic stem cell transplantation for myelofibrosis. <i>Current Opinion in Hematology</i> , 2006, 13, 74-78.	2.5	10
139	Role of theJAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. <i>Hepatology</i> , 2006, 44, 1528-1534.	7.3	249
140	Quantitative Evaluation of Bone Marrow Angiogenesis in Idiopathic Myelofibrosis. <i>American Journal of Clinical Pathology</i> , 2006, 126, 241-247.	0.7	34
141	Quantitative Evaluation of Bone Marrow Angiogenesis in Idiopathic Myelofibrosis. <i>American Journal of Clinical Pathology</i> , 2006, 126, 241-247.	0.7	13
142	Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2006, 91, 96-103.	3.5	30
143	Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2006, 91, 1662-73.	3.5	32
144	Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. <i>Blood</i> , 2005, 105, 4508-4515.	1.4	106

#	ARTICLE	IF	CITATIONS
145	Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2005, 105, 4115-4119.	1.4	194
146	Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). <i>Blood</i> , 2005, 106, 2849-2853.	1.4	75
147	The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. <i>Blood</i> , 2005, 105, 1699-1705.	1.4	58
148	Myelofibrosis With Myeloid Metaplasia: Diagnosis, Prognostic Factors, and Staging. <i>Seminars in Oncology</i> , 2005, 32, 395-402.	2.2	23
149	Studies of the Site and Distribution of CD34+ Cells in Idiopathic Myelofibrosis. <i>American Journal of Clinical Pathology</i> , 2005, 123, 833-839.	0.7	17
150	Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2α-Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia. <i>Journal of Clinical Oncology</i> , 2005, 23, 5688-5695.	1.6	81
151	Idiopathic Myelofibrosis. <i>Seminars in Hematology</i> , 2005, 42, 248-258.	3.4	35
152	Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2005, 90, 1236-57.	3.5	30
153	Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 424-431.	1.6	134
154	Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2004, 124, 618-625.	2.5	43
155	Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2004, 89, 215-32.	3.5	199
156	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). <i>Haematologica</i> , 2004, 89, 717-41.	3.5	48
157	Chronic Myeloproliferative Disorders. <i>Hematology American Society of Hematology Education Program</i> , 2003, 2003, 200-224.	2.5	101
158	Myelofibrosis with myeloid metaplasia. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 1211-1226.	2.2	35
159	Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies. <i>Leukemia and Lymphoma</i> , 2002, 43, 2301-2307.	1.3	90
160	High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy. <i>Haematologica</i> , 2002, 87, 472-8.	3.5	5
161	Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2001, 98, 3249-3255.	1.4	197
162	Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2001, 114, 78-83.	2.5	85

#	ARTICLE	IF	CITATIONS
163	Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. <i>European Journal of Haematology</i> , 2001, 66, 324-327.	2.2	26
164	Deciding when to intervene: a Markov decision process approach. <i>International Journal of Medical Informatics</i> , 2000, 60, 237-253.	3.3	40
165	Myelofibrosis With Myeloid Metaplasia: Diagnostic Definition and Prognostic Classification for Clinical Studies and Treatment Guidelines. <i>Journal of Clinical Oncology</i> , 1999, 17, 2954-2954.	1.6	208
166	The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. <i>British Journal of Haematology</i> , 1999, 104, 730-737.	2.5	179
167	Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. <i>British Journal of Haematology</i> , 1998, 102, 684-690.	2.5	168
168	Erythropoietin production and erythropoiesis in compensated and anaemic states of hereditary spherocytosis. <i>British Journal of Haematology</i> , 1996, 92, 150-154.	2.5	25
169	An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. <i>Cancer</i> , 1991, 68, 2310-2318.	4.1	33
170	A prognostic classification of myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 1988, 70, 397-401.	2.5	115
171	Red cell aplasia in myelofibrosis with myeloid metaplasia. A distinct functional and clinical entity. <i>Cancer</i> , 1983, 52, 1290-1296.	4.1	11